Concert Pharma (CNCE) Misses Q3 EPS by 11c

Concert Pharma (NASDAQ: CNCE) reported Q3 EPS of ($0.74), $0.11 worse than the analyst estimate of ($0.63). Revenue for the quarter came in at $11 thousand versus the consensus estimate of $10 thousand.

For earnings history and earnings-related data on Concert Pharma (CNCE) click here.

You May Also Be Interested In

• VNET Group (VNET) Misses Q2 EPS by 164c
• H.C. Wainwright Reiterates Buy Rating on Jasper Therapeutics (JSPR)
• iQIYI (IQ) Misses Q2 EPS by 21c